Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4592MR)

This product GTTS-WQ4592MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4592MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12748MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ2889MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ10879MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ2685MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ12030MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ3863MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ7355MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ1423MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACA125
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW